Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 3Recruiting 2Not yet recruiting 2Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1

Interventions

pembrolizumab 9fludarabine phosphate 5fludarabine 5atezolizumab 4Paclitaxel 4Nivolumab 4Cyclophosphamide 4Cisplatin 4Cetuximab 4Carboplatin 4durvalumab 3Specimen Handling 3Pemetrexed 3Docetaxel 3Bevacizumab 3venetoclax 2ibrutinib 2encorafenib 2binimetinib 2Trastuzumab 2Standard of Care 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Practice Guidelines as Topic 2Platinum 2Oxaliplatin 2Magnetic Resonance Spectroscopy 2Leucovorin 2Ipilimumab 2Gemcitabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × asciminib × 30 days × Clear all
NCT05413915 2026-05-29

Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML

Sir Mortimer B. Davis - Jewish General Hospital

Phase 3 Terminated
8 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡